ABSTRACT -Infective endocarditis (IE) is a lifethreatening disease with substantial morbidity and mortality which affects individuals with underlying structural cardiac defects who develop bacteraemia, often as a result of dental, gastrointestinal, genitourinary, respiratory or cardiac invasive/surgical procedures. Prompt recognition of the clinical diagnosis by a wide variety of medical personnel, early involvement of specialist cardiologists, cardiac surgeon and a microbiologist, and prompt treatment with the most appropriate antimicrobial agents offer the greatest chance of improving the outcome for these patients. The guidance given here to clinicians involved in the management of patients with IE briefly covers diagnosis, antibiotic prophylaxis, medical treatment and the indications for surgery.
Background
Infective endocarditis (IE) is associated with substantial morbidity and mortality, despite improved techniques to aid diagnosis and modern antibiotics and surgical therapies. 1 It affects individuals with structural cardiac defects who develop bacteraemia as a result of dental, gastrointestinal, genitourinary, respiratory or cardiac invasive/surgical procedures. 2 Most organ systems can be involved and the fact that IE may present to doctors in a variety of specialties means that they must be made aware of IE as a potential diagnosis warranting prompt specialist investigation and treatment. Guidelines for diagnosis and treatment are therefore important and worthy of widespread dissemination, such as those produced by the European Society of Cardiology: www.escardio.org/knowledge/ guidelines/Guidelines_Infective_Endocarditis.htm
Symptoms and diagnosis

When to suspect infective endocarditis
Infective endocarditis should be suspected in ill patients with known cardiac disease or new cardiac murmurs, especially if there is a history of recent dental, invasive diagnostic or surgical treatment and/or signs of embolic or vasculitic complications.
Clinical features
• Systemic features: high remitting pyrexia, rigors, anorexia, weight loss, arthralgia and fatigue. 3 • Cardiac manifestations: new or worsening cardiac murmurs -typically due to valvular regurgitation; or the development of cardiac failure. Abscesses of the heart and fistulous connections between cardiac structures are serious complications. 4 • Extracardiac manifestations consist of embolic as well as vasculitic phenomena. 5 All major vessels may be the recipient of infected emboli from valve vegetations. Renal, splenic and neurological complications may be particularly serious. Rightsided IE results in pulmonary infarcts and abscesses and is often associated with iv drug abuse, infected pacemakers or central iv lines. 6 Culture-negative IE, including fungal IE, often have specific clinical features. 7, 8 • The Duke criteria form the basis of the diagnosis of which blood cultures, echocardiography and sometimes serology are most important. 9, 10 
Bacteriology
The majority of native valve IE and of late prosthetic valve endocarditis (PVE) is caused by viridans streptococci (50-70%), Staphylococcus aureus (25%) and enterococci (10%). In early PVE, S. epidermidis and S. aureus are the commonest organisms. Gram-positive and Gram-negative bacilli, the HACEK group of organisms (Haemophilus, Actinobacillus, Cardiobacterium, Eikenella and Kingella species) and fungi are less common but serious causes of IE. Box 1. Guideline development process. These guidelines were developed in accordance with the principles laid down by the AGREE (Appraisal of Guidelines for REsearch and Evaluation Instrument) Collaboration (www.agreecollaboration.org/). The guidelines are presented in more detail, with a full reference list, on the Royal College of Physicians (RCP) website: www.rcplondon.ac.uk. An extensive referenced document is also available on the British Cardiac Society's website: www.bcs.com
SCOPE AND PURPOSE
Overall objective of the
To provide practical advice on the diagnosis, prevention and treatment of IE in adults. guidelines
The patient group covered G Individuals at risk of developing IE, eg those with congenital heart disease, valvular heart disease, prosthetic heart valves, previous IE or IV drug abuse. G Individuals presenting with the symptoms/signs of IE (eg pyrexia, new or changing heart murmurs, positive blood cultures/serology or evidence of vegetations) who have recently undergone a dental, invasive diagnostic or therapeutic procedure or surgery. 
STAKEHOLDER INVOLVEMENT
Guideline Advisory Group
A multidisciplinary group of clinicians with patient representation (for full list, see end of article).
Funding
Development of the guidelines was supported by the British Cardiac Society (BCS).
Conflicts of interest
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RIGOUR OF DEVELOPMENT
Evidence gathering
The recommendations reflect an extensive review of the literature (Medline and PubMed 1964-2003) and the personal knowledge and experience of the members of the Guideline Advisory Group.
Links between evidence
The strength of evidence and the recommendations drawn from it were classified according to the definitions and recommendations used by the Scottish Intercollegiate Guidelines Network (www.sign.ac.uk). The recommendations were graded independently by four reviewers (see end of article). Given the lack of controlled trial data from which to draw, the guidelines reflect expert consensus opinion, supported by published reports where available.
Piloting and peer review
The guidelines were reviewed by two senior UK cardiologists, both members of the BCS.
IMPLEMENTATION
Tools for application
No specific audit tools have been developed so far.
Plans for update
The guidelines are due for review in 2007 by the Endocarditis Working Group of the BCS. 
High risk
Previous IE Prosthetic heart valves Mitral valve prolapse with mitral regurgitation or thickened valve leaflets b Complex congenital heart disease Surgically constructed systemic pulmonary shunts or conduits
Moderate risk
Acquired valvular heart disease, eg rheumatic valve disease Non-cyanotic congenital cardiac defects, eg patent ductus arteriosus, coarctation of aorta, ventricular septal defect, primum atrial septal defect, bicuspid aortic valve Other structural cardiac abnormalities, eg hypertrophic obstructive cardiomyopathy, aortic root replacement a Antibiotic prophylaxis is recommended for up to 12 months after atrial septal defect/patent foramen ovale/patent ductus arteriosus catheter-based closure procedures. b Mitral regurgitation should be obvious clinically or deemed to be more than physiological on Doppler echocardiography. NB: If there is uncertainty as to the nature of the heart murmur and the need for prophylaxis, an opinion from a cardiologist should be sought. In an emergency or when it is difficult to obtain specific advice, then prophylaxis should be given prior to dental or surgical treatment.
Box 2. Guidelines on infective endocarditis: prophylaxis, diagnosis and treatment. Recommendation Grade Prophylaxis
In order to prevent IE, prophylactic antibiotic treatment is recommended prior to dental or other 'surgical' procedures for those at moderate or high risk of developing IE, should bacteraemia be induced (Table 1) . A list of dental and 'surgical' procedures requiring antibiotic prophylaxis is provided in Appendix 1, available in the more detailed guidelines on www.rcplondon.ac.uk 1 Patients should be informed of their risk of IE and the need for antibiotic prophylaxis, and be told to inform any doctor or dentist who is responsible for providing care. They should be given a card to carry indicating the type of cardiac lesion, the risk and how to avoid IE. 11-14 C 2 Patients at moderate-risk or high-risk of IE should be given antibiotic prophylaxis with appropriate antibiotics based upon the type of dental or surgical procedure being performed (Table 2) . 11,12,15-18 C
Diagnosis
When IE is suspected, the following recommendations should be followed to establish the presence or absence of the Duke criteria (Table 3) . 
Clinical situation Drug Regimen Prophylactic antibiotic regimens for dental, oral, respiratory tract or oesophageal procedures
High-risk and moderateAmoxicillin 3 g oral 1h pre-procedure or 2 g iv <30 min pre-procedure a risk patients including patients with prosthetic heart valves* If allergic to penicillin b Clindamycin c 600 mg oral 1h pre-procedure or 300 mg iv <30 min pre-procedure d then oral or iv clindamycin 150 mg 6 h later Patients with previous Amoxicillin 2 g iv <30 min pre-procedure and 1g iv or orally 6 h post procedure infective endocarditis e + gentamicin 1.5 mg/kg iv <30 min pre-procedure a If allergic to penicillin b Vancomycin 1g iv over 2 h, 1-2 h pre-procedure + gentamicin 1.5 mg/kg iv <30 min pre-procedure a or Clindamycin 300 mg iv <30 min pre-procedure d then iv clindamycin 150 mg 6 h later
Prophylactic antibiotic regimens for genitourinary or gastrointestinal procedures
High-risk and Ampicillin or amoxicillin 2 g iv -<30 min pre-procedure a and 1g iv or orally 6 h post procedure moderate-risk patients + gentamicin 1.5 mg/kg iv <30 min pre-procedure a If allergic to penicillin b Vancomycin 1 g iv over 2 h, 1-2 h pre-procedure + gentamicin 1.5 mg/kg iv <30 min pre-procedure a *Particular care should be taken to ensure that patients with prosthetic heart valves are protected by prophylactic antibiotics, since the consequences of infective endocarditis are particularly serious. It is essential that they receive prophylactic antibiotics orally at least 1 hour before the procedure. If not, they should be given iv antibiotics immediately before the procedure or the procedure should be postponed. a For those undergoing general anaesthetic, iv antibiotics should be given either on induction or within 30 min before starting the procedure; oral amoxicillin (3 g) should be given 4 hours before induction. Where oral antibiotics are not ideal and in whom iv access is difficult or impossible, eg iv drug abusers, im clindamycin 600 mg 1 hour pre-op or im teicoplanin (2 mg/kg) 1 hour pre-op may be alternative treatments. b or received penicillin within last 4 weeks. c Azithromycin 500 mg, as an oral suspension, given 1 hour before the procedure may be an alternative if dysphagia is a problem. d Clindamycin to be infused over 10-15 min. e These patients are considered to be at highest risk of IE. Table 3 . Duke criteria for diagnosis of infective endocarditis and definitions used in the modified diagnostic criteria.
Definite infective endocarditis
Pathological criteria Minor criteria 1 Predisposition: predisposing heart condition or iv drug abuse. For patients allergic to penicillin, see above.
Treatment of IE due to enterococci in adults
Gentamicin-sensitive or low-level resistant organism (MIC <500 mg/l)
Benzylpenicillin 10-12 g iv/24 h in 4-6 divided doses 4-6 weeks or ampicillin or amoxicillin 12 g iv/24 h in 4-6 divided doses 4-6 weeks d + gentamicin e,b 3-5 mg/kg iv daily in 2-3 divided doses (max 240 mg/day) 4-6 weeks d
For those allergic to penicillin, see above.
a Duration adjusted according to clinical response and advice from microbiologist. b Gentamicin blood levels must be checked regularly during this period. c Linezolid or Synercid R may be used in methicillin-resistant Staphylococcus aureus (MRSA). d Six weeks therapy recommended for patients with symptoms for >3 months. e For strains highly resistant to gentamicin (MIC >500 mg/l), ampicillin or amoxicillin 12 g iv per day in six divided doses or as a continuous infusion for 6 weeks is advisable, a microbiologist's opinion sought, and surgery considered early for antibiotic-treatment failure. For ampicillin-resistant strains, and for patients allergic to penicillin, a vancomycin + gentamicin regimen may be effective. Gentamicin and vancomycin dose will need adjustment in renal impairment. MIC = minimum inhibitory concentration.
